Mucormycosis in a liver allograft: salvage re-transplantation and targeted immunosuppressive management.
Zygomycetes infection is associated with a high mortality in transplant populations. We describe a child with liver allograft Rhizopus oryzae infection who was salvaged by liver re-transplantation. A 10-year-old child presented with anastomotic bile leak that was repaired. A combined antibiotics and voriconazole regimen was introduced for Escherichia coli and Candida krusei growth in the peritoneal fluid. Despite broad antibiotic and antifungal coverage, the patient continued to have an ongoing infection. A follow-up computed tomography scan 8 weeks later showed 2 liver abscesses infiltrating the stomach and the diaphragm, with splenic infarcts and pericardial effusion. Aspirated samples from the liver abscess and the pericardial fluid revealed R. oryzae. Immunosuppression was discontinued and an antifungal regimen combining amphotericin B, posaconazole, and caspofungin was introduced. After 3 weeks of treatment with control of the systemic signs of infection, a positron emission tomography showed the fluorescence stain limited to the liver. With infection confined to the liver, the child underwent liver re-transplantation, splenectomy, and partial gastrectomy. Immunosuppression was reintroduced with recovery of the immune response observed by the CD4 cells adenosine triphophate release (Cylex(™)  ImmuKnow(®)  assay) and posaconazole was continued for another year. At 3-year follow-up, the child maintained normal graft function. We conclude that discontinuation of immunosuppression combined with a modern antifungal regimen may allow salvage re-transplantation in patients with liver mucormycosis.
Department of Transplantation, Rabin Medical Center, Beilinson Hospital, Petach-Tiqwa, Israel.
M
M
Gurevich
I
I
Levi
R
R
Steinberg
T
T
Shonfeld
R
R
Shapiro
M
M
Israeli
H
H
Sprecher
I
I
Shalit
E
E
Mor
D000935:Antifungal Agents / Q000627:therapeutic use; D002648:Child; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008099:Liver / Q000382:microbiology; D008107:Liver Diseases / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology; D016031:Liver Transplantation / Q000009:adverse effects*; D009091:Mucormycosis / Q000175:diagnosis* / Q000276:immunology / Q000382:microbiology; D012233:Rhizopus / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification*; D014184:Transplantation, Homologous / Q000009:adverse effects
D000935:Antifungal Agents; D007166:Immunosuppressive Agents